Discovery of a potential novel pharmacogenomic biomarker on ANK3 gene for liafensine, a triple reuptake inhibitor for treatment-resistant depression
Wen Luo, Gang Wang, John W. Whitaker, Zafrin Dhali, Hong Sun, Haiping Lu, Xiaojun Li, Tao Shi, Jinkun Zhang · 2026
Read Discovery of a potential novel pharmacogenomic biomarker on ANK3 gene for liafensine, a triple reuptake inhibitor for treatment-resistant depression by Wen Luo, Gang Wang, John W. Whitaker, Zafrin Dhali, Hong Sun, Haiping Lu, Xiaojun Li, Tao Shi, Jinkun Zhang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13522506.txt.
Description
Wen Luo and co-authors search for a genetic marker that predicts response to a depression drug in a 2026 study. The drug, liafensine, blocks reuptake of three brain chemicals and had failed to help unselected patients with treatment-resistant depression in earlier trials. DNA from blood specimens of trial participants was scanned genome-wide for variants tied to improvement.
One variant in the ANK3 gene was strongly linked to response in the discovery group and confirmed in a smaller replication group. The same variant did not predict response to two other antidepressants, suggesting a drug-specific effect. A later prospective study supported the finding. The authors present the marker as an example of precision medicine, where testing guides who should receive a particular drug.
Catalog record
| CREATOR | Wen Luo, Gang Wang, John W. Whitaker, Zafrin Dhali, Hong Sun, Haiping Lu, Xiaojun Li, Tao Shi, Jinkun Zhang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39909 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |